CN115244050A - 新型hpk1抑制剂及其制备方法和应用 - Google Patents

新型hpk1抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN115244050A
CN115244050A CN202180019219.4A CN202180019219A CN115244050A CN 115244050 A CN115244050 A CN 115244050A CN 202180019219 A CN202180019219 A CN 202180019219A CN 115244050 A CN115244050 A CN 115244050A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
group
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180019219.4A
Other languages
English (en)
Other versions
CN115244050B (zh
Inventor
江磊
冯志勇
金贤
刘胜洋
石倩
寿建勇
徐圆
张建华
赵海霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yinuo Zhejiang Pharmaceutical Co ltd
Shanghai Ennovabio Pharmaceuticals Co Ltd
Original Assignee
Yinuo Zhejiang Pharmaceutical Co ltd
Shanghai Ennovabio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yinuo Zhejiang Pharmaceutical Co ltd, Shanghai Ennovabio Pharmaceuticals Co Ltd filed Critical Yinuo Zhejiang Pharmaceutical Co ltd
Publication of CN115244050A publication Critical patent/CN115244050A/zh
Application granted granted Critical
Publication of CN115244050B publication Critical patent/CN115244050B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供了一种HPK1激酶抑制剂及其制备和用途。具体地，本发明提供了一种如式I所示的化合物，其中，各基团的定义如说明书中所述。所述的化合物具有优异的HPK1抑制活性，因此可用于制备治疗癌症和其他HPK1活性相关疾病的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180019219.4A 2020-03-03 2021-03-03 新型hpk1抑制剂及其制备方法和应用 Active CN115244050B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010140894.XA CN113336747A (zh) 2020-03-03 2020-03-03 新型hpk1抑制剂及其制备方法和应用
CN202010140894X 2020-03-03
PCT/CN2021/078966 WO2021175271A1 (zh) 2020-03-03 2021-03-03 新型hpk1抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN115244050A true CN115244050A (zh) 2022-10-25
CN115244050B CN115244050B (zh) 2024-06-21

Family

ID=77467421

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010140894.XA Pending CN113336747A (zh) 2020-03-03 2020-03-03 新型hpk1抑制剂及其制备方法和应用
CN202180019219.4A Active CN115244050B (zh) 2020-03-03 2021-03-03 新型hpk1抑制剂及其制备方法和应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010140894.XA Pending CN113336747A (zh) 2020-03-03 2020-03-03 新型hpk1抑制剂及其制备方法和应用

Country Status (2)

Country Link
CN (2) CN113336747A (zh)
WO (1) WO2021175271A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
WO2023143344A1 (zh) * 2022-01-30 2023-08-03 微境生物医药科技(上海)有限公司 新型egfr抑制剂
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106817900A (zh) * 2014-07-17 2017-06-09 默克专利有限公司 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途
CN110678466A (zh) * 2017-03-30 2020-01-10 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
CN110709392A (zh) * 2017-03-30 2020-01-17 豪夫迈·罗氏有限公司 作为hpk1抑制剂的异喹啉

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106817900A (zh) * 2014-07-17 2017-06-09 默克专利有限公司 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途
CN110678466A (zh) * 2017-03-30 2020-01-10 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
CN110709392A (zh) * 2017-03-30 2020-01-17 豪夫迈·罗氏有限公司 作为hpk1抑制剂的异喹啉

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AURÉLIE MALLINGER ET AL.: "2, 8-Disubstituted-1, 6-Naphthyridines and 4, 6-Disubstituted- Isoquinolines with Potent, Selective Affinity for CDK8/19", 《ACS MEDICINAL CHEMISTRY LETTERS》, vol. 7, no. 6, pages 573 - 578, XP055581057, DOI: 10.1021/acsmedchemlett.6b00022 *

Also Published As

Publication number Publication date
CN113336747A (zh) 2021-09-03
CN115244050B (zh) 2024-06-21
WO2021175271A1 (zh) 2021-09-10

Similar Documents

Publication Publication Date Title
EP3917927A1 (en) Immunomodulators, compositions and methods thereof
CN115244050B (zh) 新型hpk1抑制剂及其制备方法和应用
AU2017268536B2 (en) Novel compounds and compositions for inhibition of FASN
US9737516B2 (en) Bicyclic heterocycles as bet protein inhibitors
CN113354648A (zh) 新型hpk1抑制剂及其制备方法和应用
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
AU2013344049B2 (en) ALK kinase inhibitors
CA3204823A1 (en) Prmts inhibitors
WO2014160873A1 (en) Benzimidazolone derivatives as bromodomain inhibitors
KR20220028072A (ko) Bet 억제제로서의 헤테로시클릭 화합물
CA3117850A1 (en) Ret inhibitors, pharmaceutical compositions and uses thereof
CN113968856B (zh) 一类具有激酶抑制活性的化合物
KR20190098266A (ko) 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
WO2020125759A1 (zh) 作为wnt信号通路抑制剂的化合物及其医学应用
CN116410207A (zh) 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
CN118055933A (zh) 选择性parp1抑制剂及其应用
JP7420403B2 (ja) キナーゼ阻害剤として使用される化合物およびその応用
KR101739003B1 (ko) 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
CN113164481A (zh) 环烷-1,3-二胺衍生物
CN115746026A (zh) 吡咯并嘧啶类衍生物及其制备方法和应用
CN115433161A (zh) 新型hpk1抑制剂及其制备方法和应用
KR102539761B1 (ko) 2-티옥소티아졸리딘-4-온 유도체 화합물 및 이의 용도
CN116143779A (zh) 一种造血祖细胞激酶1抑制剂的化合物及其制备方法和应用
AU2022316931A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
CN116655636A (zh) 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant